Amprius Stock Plummets 28% After Short Seller Alleges Fraud
0h ago|4 min readStandard
Fazen Markets Editorial Desk
Collective editorial team · methodology
amprius-technologiesshort-seller
Fazen Markets Editorial Desk
Collective editorial team · methodology
Trades XAUUSD 24/5 on autopilot. Verified Myfxbook performance. Free forever.
Risk warning: CFDs are complex instruments and come with a high risk of losing money rapidly due to leverage. The majority of retail investor accounts lose money when trading CFDs. Vortex HFT is informational software — not investment advice. Past performance does not guarantee future results.
Shares of Amprius Technologies Inc., a developer of high-energy-density lithium-ion batteries, fell sharply in trading on 20 May 2026 after a short seller published a detailed report alleging fraudulent reporting of key manufacturing metrics. Investing.com reported that the stock slid 28% from its previous close to $8.42. The report from short seller research firm Frostbite Capital accuses Amprius of misrepresenting the viability and commercial prospects of its proprietary silicon anode technology, which is central to the company's valuation thesis.
This is the most significant public short attack on a battery technology company since 24 September 2024, when Blue Ocean Capital targeted rival Enovix Corp., alleging similar exaggeration of production yields. That report triggered a 41% single-day decline for Enovix and led to a multi-year decline in investor confidence in next-generation battery stocks. The current macro backdrop for battery and electric vehicle equities remains challenging, with capital markets tight and the Nasdaq Clean Edge U.S. Liquid Series Index down 4.3% year-to-date.
The catalyst for the Frostbite report's immediate impact is the specific timing of operational milestones. Amprius recently announced the commissioning of its first commercial-scale production facility in Colorado. The short seller's allegations directly challenge the validity of the efficiency and yield data provided from this pilot line, which investors have used to model future profitability. The report's publication coincided with a period of elevated short interest in the stock, which had climbed to 18% of the float ahead of the announcement.
The stock's decline erased approximately $480 million in market capitalization, moving from a pre-report market cap of $1.71 billion to approximately $1.23 billion. Trading volume exploded to 42.8 million shares, a staggering 2,150% increase over its 30-day average volume of 1.9 million shares. The intraday low reached $7.85, marking a 33% decline from the previous day's close before a slight recovery. The collapse brought the stock to a level 76% below its 52-week high of $35.10, reached on 12 November 2025.
Before the report, Amprius shares had significantly outperformed its peer group, gaining 15% year-to-date versus an average decline of 8% for the S&P Kensho Electric Vehicles Index. The short seller's core allegation centers on the company's claimed production yield of 96% for its silicon nanowire anodes. Frostbite asserts that independent technical analysis suggests actual yields are below 70%, which would render the commercial process uneconomical at current cost structures.
The immediate second-order effect is a sharp reversal of recent momentum in the advanced battery technology sector. Direct competitors like QuantumScape Corp. (QS) and Solid Power Inc. (SLDP) saw their stocks decline 6.5% and 4.2%, respectively, on fears of a generalized investor retreat from pre-revenue, technology-focused battery plays. Conversely, established lithium-ion battery companies using conventional graphite anode technology, such as Panasonic Holdings and LG Energy Solution, saw their U.S.-listed ADRs rise marginally as the report casts doubt on the near-term threat from silicon anodes.
A key risk to the short thesis is the potential for a swift and detailed public rebuttal from Amprius management. The company has scheduled an investor call for 21 May 2026, where it is expected to refute the claims. A credible technical defense could trigger a significant short squeeze, given the elevated short interest. Current positioning shows hedge funds and institutional investors as net sellers on the day, while some high-frequency trading desks provided liquidity during the sell-off. Flow data indicates retail investors were net buyers into the sharp decline, a common pattern during extreme volatility events.
Investors should watch for the company's official response on the scheduled investor call, 21 May 2026. The credibility of any provided data, such as third-party audit reports or detailed production logs, will be critical for restoring confidence. The next major catalyst is the Q2 2026 earnings report, scheduled for 7 August 2026, where updated financial guidance and capital expenditure plans will be scrutinized for any adjustments reflecting the allegations.
Key technical levels for the stock include the $7.50 support level, which represents the stock's IPO price from November 2022. A breach below this level would signal a complete loss of confidence from the initial public offering investor base. On the upside, initial resistance is seen at the $10.00 psychological level, which also aligns with the stock's 50-day simple moving average. If the company successfully debunks the report, a move back above $12.50 would invalidate the bearish technical structure established by the sell-off.
The Frostbite Capital report alleges that Amprius Technologies has systematically misrepresented the production yield and cost-effectiveness of its silicon nanowire anode manufacturing process. The report claims internal documents and engineering analysis show true production yields are significantly below the 96% rate publicly touted by management. This alleged overstatement makes the company's projected gross margins and path to profitability non-viable, according to the short seller, which questions the fundamental economics of its entire business model.
The attack on Amprius shares structural similarities with the 2024 short report on Enovix, which also focused on production yield claims. However, the Amprius allegation is more narrowly technical, targeting a single, specific manufacturing metric rather than a broader suite of business practices. The market reaction for Amprius (-28%) was less severe than Enovix's initial -41% drop, potentially indicating a more measured initial assessment from the broader market or lower perceived credibility of the current short seller's claims.
Legal action is a common but high-risk response. A defamation lawsuit would trigger a protracted discovery process, potentially forcing Amprius to disclose sensitive internal production data and communications in court. This creates a binary outcome: the data could conclusively prove the company's claims, leading to a total vindication and stock recovery, or it could confirm the short seller's allegations, resulting in catastrophic losses and potential delisting. Most companies opt for a detailed public rebuttal with supporting evidence before pursuing litigation.
A short seller's fraud allegations have shattered investor confidence in Amprius's core technology, triggering a collapse that now hinges entirely on management's ability to provide verifiable proof of its manufacturing claims.
Disclaimer: This article is for informational purposes only and does not constitute investment advice. CFD trading carries high risk of capital loss.
Vortex HFT is our free MT4/MT5 Expert Advisor. Verified Myfxbook performance. No subscription. No fees. Trades 24/5.
Trade 800+ global stocks & ETFs
Start TradingSponsored
Open a demo account in 30 seconds. No deposit required.
CFDs are complex instruments and come with a high risk of losing money rapidly due to leverage. You should consider whether you understand how CFDs work and whether you can afford to take the high risk of losing your money.